8-K: INVO Fertility Secures $4M Private Placement

INVO Fertility, Inc. announced a $4.0 million private placement of common stock and warrants to fund acquisitions, debt, and working capital.

Summary

• INVO Fertility, Inc. (NASDAQ: IVF) entered into a securities purchase agreement for a $4.0 million private placement with an institutional investor.
• The private placement includes 235,000 shares of common stock, pre-funded common stock purchase warrants to purchase 2,131,864 shares, and common stock purchase warrants to purchase 4,733,728 shares.
• The combined effective offering price for each share of common stock (or pre-funded warrant in-lieu thereof) and accompanying warrants is $1.69.
• Pre-funded warrants are immediately exercisable at a nominal exercise price of $0.0001 per share.
• Common warrants have an exercise price of $1.69 per share, will be exercisable upon shareholder approval, and expire on the five-year anniversary from such approval date.
• Gross proceeds from the private placement are approximately $4.0 million, before deducting placement agent fees and other estimated offering expenses.
• Net proceeds will be utilized for: up to $300,000 for the purchase price of Family Beginnings, P.C.; up to $75,000 for expenses related to this acquisition; up to $938,000 towards outstanding debt obligations; and the balance for working capital and general corporate purposes.
• Maxim Group LLC acted as the sole placement agent, receiving an 8.0% cash fee of the gross proceeds and warrants to purchase up to 118,343 shares of common stock at an exercise price of $2.1125 per share.
• The company also reimbursed the placement agent for certain expenses and legal fees up to $50,000.
• A registration rights agreement was entered into, requiring the company to file a registration statement for the resale of all purchased securities.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding for strategic growth and debt reduction, which is positive. However, the significant potential for dilution from the warrants and the contingency of shareholder approval for common warrants introduce uncertainty and potential negative pressure on the stock. The 'at-the-market' pricing suggests no significant premium or discount, making it a relatively neutral event in terms of immediate valuation impact, but the long-term implications of dilution are a concern.

Positives

• Successfully raised $4.0 million in capital, providing essential funding for strategic initiatives and operational needs.
• Proceeds are allocated to a specific acquisition (Family Beginnings, P.C.), debt reduction, and general working capital, indicating a clear financial strategy.
• The private placement was priced 'at-the-market' under Nasdaq rules, suggesting a valuation aligned with current market conditions.
• Pre-funded warrants offer immediate exercisability at a nominal price, potentially providing quick capital infusion upon exercise.
• The company is actively expanding its assisted reproductive technology (ART) care through building, acquiring, and operating fertility clinics, aligning with market growth.

Negatives

• Significant potential dilution from the issuance of 235,000 shares and warrants to purchase an additional 6,865,592 shares (plus placement agent warrants for 118,343 shares), totaling over 7 million shares.
• Common Warrants require stockholder approval to become exercisable, introducing a contingency and potential delay in full capital realization.
• The company incurs substantial costs for the capital raise, including an 8.0% cash fee ($320,000) and warrants to the placement agent, plus up to $50,000 in expense reimbursement.
• The company is prohibited from issuing new equity or entering into Variable Rate Transactions for specified periods, limiting future financing flexibility.
• The need for a capital raise, with a portion allocated to outstanding debt, could suggest existing liquidity pressures or significant ongoing funding requirements.

Risks

• The issuance of a large number of shares and warrants could significantly dilute the ownership and voting power of existing shareholders.
• The exercisability of Common Warrants is contingent on stockholder approval to increase authorized shares and comply with Nasdaq rules, which may not be obtained or could be delayed.
• Future open market or derivative transactions by purchasers, including short sales, may negatively impact the market price of the company's publicly-traded securities.
• Failure to comply with SEC filing requirements for registration statements or maintain public information could result in liquidated damages.
• The use of proceeds for an acquisition (Family Beginnings, P.C.) and general corporate purposes carries inherent integration and execution risks.
• Covenants restricting future equity issuances and Variable Rate Transactions could limit the company's ability to raise additional capital quickly if needed.
• The company's reliance on its INVOcell technology and expansion into fertility clinics carries market adoption and competitive risks.

Future Outlook

The company intends to use the net proceeds from the private placement to fund the acquisition of Family Beginnings, P.C., reduce outstanding debt, and for general working capital purposes. It also plans to continue its strategy of building, acquiring, and operating fertility clinics and selling its INVOcell technology. The company will seek stockholder approval by January 8, 2026, to increase authorized shares and comply with Nasdaq rules, which is crucial for the full exercisability of the common warrants.

Management Comments

• INVO Fertility, Inc. (NASDAQ: IVF), a healthcare company focused on the fertility market, has entered into a securities purchase agreement with a single institutional investor to purchase 2,366,864 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 4,733,728 shares of common stock, in a private placement priced at-the-market under Nasdaq rules.
• The company intends to utilize up to $300,000 of the net proceeds to fund the purchase price for Family Beginnings, P.C., up to $75,000 towards expenses related to the purchase of Family Beginning, P.C., up to $938,000 towards outstanding debt obligations that are or will become payable, and the balance of the net proceeds for working capital and general corporate purposes.
• We are a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. Our principal commercial strategy is focused on building, acquiring and operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by our INVOcell medical device (INVOcell) and US-based, profitable in vitro fertilization (IVF) clinics.

Industry Context

The fertility market is experiencing growth, driven by increasing demand for assisted reproductive technologies (ART). INVO Fertility's strategy to expand ART care through clinic acquisitions and the distribution of its INVOcell technology aligns with this trend. The INVOcell device, offering an intravaginal culture (IVC) procedure, positions the company to provide a more natural, intimate, and potentially more affordable alternative to traditional IVF, which could capture a larger segment of the market seeking cost-effective fertility solutions. The acquisition of Family Beginnings, P.C. further solidifies its presence and service offerings in the sector.

Comparison to Industry Standards

• The 'at-the-market' pricing of $1.69 per share/pre-funded warrant suggests the offering was aligned with the prevailing market valuation for INVO Fertility's stock, which is a common practice for private placements to institutional investors.
• The 8.0% placement agent fee is within the typical range for private placements of this size, which can vary from 5% to 10% depending on the deal size and complexity.
• The issuance of warrants to the placement agent (5% of the shares/pre-funded warrants sold) is also a standard component of compensation in such transactions, providing an additional incentive for the agent.
• The requirement for shareholder approval for the common warrants to become exercisable is a common regulatory hurdle for Nasdaq-listed companies when issuing securities that could exceed 20% of outstanding shares, ensuring compliance with exchange rules against excessive dilution without shareholder consent.
• The inclusion of liquidated damages for delays in registration statement effectiveness is a standard protective clause for investors in private placements, ensuring timely liquidity for their restricted securities.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution from the issuance of new shares and the exercise of warrants, which could decrease the value of existing holdings.
• Investors (Purchasers in Private Placement): Will acquire common stock and warrants, with potential for future gains if the company's strategy succeeds, and benefit from registration rights for liquidity.
• Employees: The capital raise and strategic initiatives (like acquisitions) could lead to business growth, potentially benefiting employees through job security or expansion.
• Creditors: A portion of the proceeds is allocated to repay outstanding debt, which is positive for creditors as it reduces the company's leverage and improves its financial health.
• Customers (Fertility Patients): The acquisition of Family Beginnings, P.C. and expansion of ART care could lead to broader access to fertility services, including the INVOcell technology.

Next Steps

• The company expects to close the offering on or about December 3, 2025.
• The company will file a Current Report on Form 8-K, including the Transaction Documents as exhibits.
• The company will file a registration statement with the SEC for the resale of the securities purchased in the private placement.
• The company will hold a special meeting of stockholders by January 8, 2026, to obtain approval for increasing authorized shares and complying with Nasdaq rules for the common warrants. If not obtained, meetings will be called every four months thereafter.
• The company will apply to list all newly issued shares and warrant shares on the Nasdaq Stock Market.

Key Dates

Recommendation

The capital raise provides essential funding for INVO Fertility's strategic growth initiatives, including an acquisition and debt reduction, which are positive for the company's long-term stability and expansion in the fertility market. However, the significant potential for dilution from the large number of warrants issued, coupled with the contingency of shareholder approval for a substantial portion of these warrants, introduces considerable uncertainty and potential downward pressure on the stock price. The 'at-the-market' pricing suggests a fair current valuation, but the dilutive effects could offset immediate gains. Investors should hold to monitor the execution of the acquisition, the impact of debt reduction, and the outcome of the shareholder vote, as these factors will be critical in determining the stock's future performance. The long-term growth potential in the ART market is attractive, but the short-to-medium term risks associated with dilution and contingent approvals warrant a cautious approach.

Keywords

INVO Fertility, IVF, Private Placement, Common Stock, Warrants, Pre-Funded Warrants, Capital Raise, SEC Filing, Form 8-K, Fertility Market, Assisted Reproductive Technology, INVOcell, Nasdaq, Dilution, Shareholder Approval, Maxim Group LLC, Family Beginnings P.C., Debt Repayment, Working Capital